Juan Ruiz Martín

Juan Ruiz Martín


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in United European Gastroenterology Journal
Verified
Journal Article
Open access
JVJulio Valle
Julio Valle
JMJosé Mario T Morgado
José Mario T Morgado
JMJuan Ruiz Martín
Juan Ruiz Martín
AGAntonio Guardiola
Antonio Guardiola
MLMiriam Lopes‐Nogueras
Miriam Lopes‐Nogueras
LSLaura Sánchez-Muñoz
Laura Sánchez-Muñoz
Background: Diagnosis of celiac disease is difficult when the combined results of serology and histology are inconclusive. Studies using flow cytometry of intraepithelial lymphocytes (IELs) have found that celiac patients have increased numbers of γδ IELs, along with a decrease in CD3‐CD103 + IELs.Objective: The objective of this article is to assess the role of flow cytometric analysis of IELs in the diagnosis of celiac disease in difficult cases.Methods: A total of 312 patients with suspicion of celiac disease were included in the study. Duodenal biopsy samples were used for histological assessment and for flow cytometric analysis of IELs.Results: In 46 out of 312 cases (14.7%) the combination of serology and histology did not allow the confirmation or exclusion of celiac disease. HLA typing had been performed in 42 of these difficult cases. Taking into account HLA typing and the response to a gluten‐free diet, celiac disease was excluded in 30 of these cases and confirmed in the remaining 12. Flow cytometric analysis of IELs allowed a correct diagnosis in 39 out of 42 difficult cases (92.8%) and had a sensitivity of 91.7% (95% CI: 61.5% to 99.8%) and a specificity of 93.3% (95% CI: 77.9% to 99.2%) for the diagnosis of celiac disease in this setting.Conclusion: Flow cytometric analysis of IELs is useful for the diagnosis of celiac disease in difficult cases.

21 September 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ECEliana Canicattì
Eliana Canicattì
Daniel Alvarez Sánchez-BayuelaDaniel Alvarez Sánchez-Bayuela
Daniel Alvarez Sánchez-Bayuela
CCCristina Romero Castellano
Cristina Romero Castellano
PAPaul Martín Aguilar Angulo
Paul Martín Aguilar Angulo
RGRubén Giovanetti González
Rubén Giovanetti González
AMAgostino Monorchio
Agostino Monorchio
Dielectric characterization has significant potential in several medical applications, providing valuable insights into the electromagnetic properties of biological tissues for disease diagnosis, treatment planning, and monitoring of therapeutic interventions. This work presents the use of a custom-designed electromagnetic characterization system, based on an open-ended coaxial probe, for discriminating between benign and malignant breast tissues in a clinical setting. The probe’s development involved a well-balanced compromise between physical feasibility and its combined use with a reconstruction algorithm known as the virtual transmission line model (VTLM). Immediately following the biopsy procedure, the dielectric properties of the breast tissues were reconstructed, enabling tissue discrimination based on a rule-of-thumb using the obtained dielectric parameters. A comparative analysis was then performed by analyzing the outcomes of the dielectric investigation with respect to conventional histological results. The experimental procedure took place at Complejo Hospitalario Universitario de Toledo—Hospital Virgen de la Salud, Spain, where excised breast tissues were collected and subsequently analyzed using the dielectric characterization system. A comprehensive statistical evaluation of the probe’s performance was carried out, obtaining a sensitivity, specificity, and accuracy of 81.6%, 61.5%, and 73.4%, respectively, compared to conventional histological assessment, considered as the gold standard in this investigation.

29 March 2021 in Journal of Medical Screening
Verified
Journal Article
Open access
PDF file
CCCristina Romero Castellano
Cristina Romero Castellano
PAPaul Martin Aguilar Angulo
Paul Martin Aguilar Angulo
LHLina Cruz Hernández
Lina Cruz Hernández
PGPilar Sánchez-Camacho González-Carrato
Pilar Sánchez-Camacho González-Carrato
RGRubén Giovanetti González
Rubén Giovanetti González
GÁGonzalo Gutiérrez Ávila
Gonzalo Gutiérrez Ávila
Objectives: To assess screening quality metrics and to describe mortality rates eight years after redesign of breast cancer screening and diagnosis pathways, and the introduction of digital breast tomosynthesis. Setting: Breast Unit of the Toledo Health Area in the region of Castilla-La Mancha (Spain). Methods: We recorded screening metrics and mortality data following the introduction of digital breast tomosynthesis in 2011 for screening and diagnosis pathways. We then compared the mortality between Toledo Health Area and the rest of Castilla-La Mancha, where digital breast tomosynthesis is not available. Results: All screening quality metrics improved following the introduction of digital breast tomosynthesis. The cancer detection rate significantly increased from 2.3 (95% confidence interval (CI): 1.9–3.6) to 4.5 per 1000 women (95% CI: 3.2–5.2) on average between the periods 2005–2009 and 2015–2018, while the recall rate significantly decreased from 7.0% (95% CI: 6.8%–8.2%) to 2.6% (95% CI: 2.0%–3.6%). Comparing breast cancer mortality rates for 2014–2018 in the Toledo Health Area with the rest of Castilla-La Mancha, which had similar cancer treatment access and management protocols but without digital breast tomosynthesis, the crude mortality rate was 17.79 (95% CI: 15.38 -20.19) vs. 24.76 per 100,000 (95% CI: 26.12–23.39), respectively. The cumulative risk of death was also significantly lower for the Toledo Health Area than for Castilla-La Mancha. Conclusion: The introduction of digital breast tomosynthesis improved screening quality indicators. Breast cancer mortality simultaneously decreased with respect to the rest of Castilla-La Mancha. Further research is needed to assess the long-term results, and the role that the redesign may have played in reducing mortality.

13 August 2018 in British Journal of Radiology
Verified
Journal Article
Closed access
MGMaría Pilar Sánchez-Camacho González-Carrato
María Pilar Sánchez-Camacho González-Carrato
CCCristina Romero Castellano
Cristina Romero Castellano
PAPaul Martín Aguilar Angulo
Paul Martín Aguilar Angulo
LHLina Marcela Cruz Hernández
Lina Marcela Cruz Hernández
MCMarcelino Sánchez Casado
Marcelino Sánchez Casado
Vicente Martinez VizcainoVicente Martinez Vizcaino
Vicente Martinez Vizcaino
Objective: To assess the clinical performance of the halo sign in tomosynthesis and synthesized 2D mammography, and to identify age groups where its diagnostic value may be greater. Methods: 183 patients with nodules were recalled from the breast screening programme (with tomosynthesis and 2D synthesized mammograms). The patients were separated into two groups, 45–49 years and 50–69 years, and depending on the presence or not of halo sign. We calculated the predictive values for the different age groups. Results: In 45–49 years group, 86 nodular lesions were recalled, 66 (76.7%) with positive halo sign and 20 (23.3%) with negative halo sign. In positive halo sign group, biopsy was considered in 23 (34.8%), with histological features of benignity. In 50–69 years group, 98 nodular lesions from 97 patients were recalled, 51 (52%) with positive halo sign and 47 (48%) with negative halo sign. In positive halo sign group, biopsy was considered in 13 (25.5%); four (30.8%) were malignant and nine (69.2%) were benign. Conclusion: Halo sign could be considered as a marker of benign lesion in females < 50 years. In females ≥ 50 years, other breast imaging techniques should be considered, with or without histological studies, to rule out malignancy. Advances in knowledge: The trend of a positive halo sign to act as a marker of benign lesion could be improve the recall rate and positive predictive values in the breast screening programme with tomosynthesis and synthesized 2D mammography, especially in young females.

30 June 2013 in Pathology - Research and Practice
Verified
Journal Article
Closed access
JMJuan Ruiz Martín
Juan Ruiz Martín
CSConsuelo Pérez Sánchez
Consuelo Pérez Sánchez
ACAlicia de Las Heras Camino
Alicia de Las Heras Camino

Verified
Journal Article
Open access
PDF file
ÁRÁngel Romo-Navarro
Ángel Romo-Navarro
JMJuan Ruiz Martín
Juan Ruiz Martín
Irene García-Camacha GutiérrezIrene García-Camacha Gutiérrez
Irene García-Camacha Gutiérrez
Mariano Amo-SalasMariano Amo-Salas
Mariano Amo-Salas
MPMaría Recuero Pradillo
María Recuero Pradillo
YCYolanda Campos-Martín
Yolanda Campos-Martín
Up to 25% of stage II colorectal adenocarcinomas recur within the first five years after diagnosis. The assessment of the stromal percentage, recently incorporated into the TNM classification system, may represent a particularly relevant predictive factor for recurrence in cases with microsatellite stability. We evaluated disease-free survival (DFS) in an independent retrospective cohort, measured the stromal percentage across the entire invasive front of the tumor, and assessed the interobserver agreement of this measurement method. Among 131 cases, 16 (12.2%) showed a high stromal percentage and 115 (87.8%) a low one. A high stromal percentage was associated with high-grade budding (p = 0.006). The 5-year DFS was 57% for high-stroma cases versus 76% for low-stroma cases (p < 0.001). Lymphatic invasion (HR: 16.513; p < 0.001) and a high stromal percentage (HR: 4.366; p = 0.006) had a statistically significant correlation with DFS. Interobserver agreement for global stromal assessment was very good (kappa index = 0.870; p < 0.001). In conclusion, the stromal percentage may be a predictive factor for recurrence, particularly relevant in stage II microsatellite-stable colorectal adenocarcinomas. Global stromal assessment appears to be a simple and easily reproducible method.